Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) EPS (Basic) (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of EPS (Basic) data on record, last reported at $0.03 in Q3 2025.

  • For Q3 2025, EPS (Basic) fell 25.0% year-over-year to $0.03; the TTM value through Sep 2025 reached $0.08, up 153.33%, while the annual FY2024 figure was $0.04, 66.67% down from the prior year.
  • EPS (Basic) reached $0.03 in Q3 2025 per PLX's latest filing, up from $0.01 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.29 in Q2 2023 and bottomed at -$0.25 in Q2 2021.
  • Average EPS (Basic) over 5 years is -$0.04, with a median of -$0.05 recorded in 2022.
  • Peak YoY movement for EPS (Basic): plummeted 566.67% in 2021, then soared 363.64% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$0.14 in 2021, then surged by 50.0% to -$0.07 in 2022, then plummeted by 42.86% to -$0.1 in 2023, then soared by 190.0% to $0.09 in 2024, then tumbled by 66.67% to $0.03 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were $0.03 in Q3 2025, $0.01 in Q2 2025, and -$0.05 in Q1 2025.